Serum concentrations of two endometrial proteins are not useful for monitoring postmenopausal estrogen/progesterone therapy.
Measurements of the serum concentrations of the endometrial proteins IGFBP-1 and PP14 were made in an attempt to monitor the adequacy of the P effect in women receiving 1 year of 100 to 200 micrograms of percutaneous E2 for 28 days each month and 10 mg oral MPA given during the last 12 days of E2 administration. There were no significant changes in IGFBP-1 levels; a small, but significant increase in PP14 levels after E2 plus MPA was noted, but there was substantial overlap between basal and postprogestogen therapy serum PP14 concentrations. Serum concentrations of PP14, but not IGFBP-1, were slightly higher in women whose endometrial biopsies demonstrated a P effect, but again, there was substantial overlap with the values found in women whose biopsies showed only an estrogen effect. Serum measurements of IGFBP-1 and PP14 are not useful for monitoring postmenopausal replacement therapy with percutaneous E2 and oral MPA.
Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California 90048.
S G
SG
Ren
G D
GD
Braunstein
M
M
Cedars
J
J
Gambone
H
H
Judd
D000328:Adult; D000368:Aged; D002352:Carrier Proteins / Q000097:blood* / Q000276:immunology; D004717:Endometrium / Q000187:drug effects / Q000378:metabolism; D004958:Estradiol / Q000627:therapeutic use*; D015914:Estrogen Replacement Therapy / Q000379:methods*; D005260:Female; D000071816:Glycodelin; D006023:Glycoproteins; D006801:Humans; D018969:Insulin-Like Growth Factor Binding Proteins; D008593:Menopause / Q000097:blood*; D008875:Middle Aged; D011257:Pregnancy Proteins / Q000097:blood* / Q000276:immunology; D011374:Progesterone / Q000502:physiology / Q000627:therapeutic use*; D011863:Radioimmunoassay
D002352:Carrier Proteins; D000071816:Glycodelin; D006023:Glycoproteins; D018969:Insulin-Like Growth Factor Binding Proteins; C045246:PAEP protein, human; D011257:Pregnancy Proteins; D011374:Progesterone; D004958:Estradiol